Welcome to our dedicated page for Entrada Therapeutics SEC filings (Ticker: TRDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Entrada Therapeutics, Inc. (Nasdaq: TRDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Entrada is a clinical-stage biopharmaceutical company developing RNA- and protein-based therapeutics using its Endosomal Escape Vehicle (EEV™) technology for neuromuscular, ocular and other diseases.
For TRDA, key filings include periodic reports and current reports on Form 8-K. Recent Form 8-K filings furnished by Entrada cover quarterly financial results and corporate updates, such as results for the quarters ended June 30, 2025 and September 30, 2025. These filings confirm that Entrada’s common stock is registered on The Nasdaq Global Market under the symbol TRDA and identify the company as an emerging growth company.
Through this page, users can review how Entrada reports on its financial condition, collaboration revenue, research and development expenses, and other operating metrics in documents that are incorporated by reference into its SEC record. While the detailed content of annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy statements is not reproduced here, this filings hub is the starting point for locating those documents on EDGAR.
Stock Titan enhances access to Entrada’s SEC filings by organizing them chronologically and highlighting document types that matter to investors, such as Forms 8-K, 10-K, 10-Q and, when applicable, insider transaction reports on Form 4. AI-driven tools can help summarize lengthy filings and clarify technical language, allowing readers to more quickly understand how Entrada describes its EEV platform, clinical programs and financial results in its official regulatory disclosures.
Entrada Therapeutics, Inc. reported that President of Research & Development Sethuraman Natarajan received new equity awards and had shares disposed to cover tax obligations. On March 1, 2026, he was granted 55,800 restricted stock units (RSUs), each representing one share of common stock, scheduled to vest 25% each on March 1, 2027, March 1, 2028, March 1, 2029, and March 1, 2030, contingent on continued service. He also received a stock option for 83,200 shares of common stock, with 25% vesting on March 1, 2027 and the remaining 75% vesting in 36 equal monthly installments through March 1, 2030. To satisfy minimum statutory tax withholding obligations, the company automatically sold shares on his behalf: 3,898 shares of common stock on March 2, 2026 at a weighted average price of $11.6579 (across trades from $11.17 to $11.91) and 7,577 shares on March 3, 2026 at a weighted average price of $11.7564 (across trades from $11.22 to $12.095). After these transactions, he directly owned 242,224 shares of Entrada’s common stock.
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing intracellular genetic medicines, led by exon-skipping therapies for Duchenne muscular dystrophy (DMD) and a partnered program for myotonic dystrophy type 1 (DM1) with Vertex.
In 2026, the company plans data readouts from multiple DMD trials, including ENTR‑601‑44 and ENTR‑601‑45, and regulatory progress for ENTR‑601‑50 and ENTR‑601‑51. Vertex’s VX‑670 DM1 trial is expected to complete enrollment and dosing in mid‑2026. Entrada is also advancing ENTR‑801 for Usher syndrome type 2A and a broader ocular and preclinical pipeline based on its Endosomal Escape Vehicle (EEV) platform.
Entrada Therapeutics reported fourth-quarter and full-year 2025 results that reflect a shift from collaboration-driven revenue to heavier investment in its genetic medicines pipeline. Collaboration revenue fell to $1.3 million in the fourth quarter and $25.4 million for 2025, down from $37.4 million and $210.8 million in 2024, mainly because work under the VX-670 collaboration research plan substantially finished in early 2025.
Research and development spending rose to $142.3 million for 2025, helping drive a full-year net loss of $143.8 million after net income of $65.6 million in 2024. The company ended 2025 with $295.7 million in cash, cash equivalents and marketable securities and expects this to fund operations into the third quarter of 2027. Entrada highlighted progress across multiple Duchenne muscular dystrophy programs, including a positive independent committee recommendation to escalate dosing in the ELEVATE-44-201 study, and outlined clinical data readouts expected throughout 2026.
Entrada Therapeutics reported preliminary cash, cash equivalents and marketable securities of $296 million as of December 31, 2025, and indicated its cash resources are expected to be sufficient into the third quarter of 2027. This estimate is unaudited and may change when the year-end audit is completed.
The company outlined major progress in its RNA-based therapeutics pipeline for neuromuscular and ocular diseases. It completed dosing of Cohort 1 in the global Phase 1/2 multiple ascending dose study of ENTR-601-44 in Duchenne muscular dystrophy and moved into the open-label Phase 2 portion, with first cohort data from ELEVATE-44-201 expected in Q2 2026. The FDA granted Rare Pediatric Disease Designation to ENTR-601-44, regulators in the U.K. authorized a Phase 1/2 study of ENTR-601-50, and Entrada plans additional studies and filings for ENTR-601-45, ENTR-601-50, ENTR-601-51 and ocular candidate ENTR-801 through 2026, alongside continued development of its partnered VX-670 program.
Entrada Therapeutics, Inc. (TRDA) reported an insider stock sale by its Chief Financial Officer. On 11/21/2025, the CFO sold 8,910 shares of common stock in an open-market transaction at a weighted average price of $9.9811 per share. The shares were sold in multiple trades at prices ranging from $9.95 to $10.05.
The transaction was executed pursuant to a Rule 10b5-1 trading plan that the reporting person adopted on March 6, 2025. Following this sale, the CFO beneficially owns 110,026 shares of Entrada Therapeutics common stock in direct ownership.
Entrada Therapeutics, Inc. (TRDA) reported open-market purchases of its common stock by Baker Brothers–affiliated investment funds and related reporting persons. On November 20, 2025, the funds bought multiple blocks of Entrada common stock, including 1,213 and 1,186 shares at weighted-average prices of $9.0688 and $9.0728, respectively. Additional blocks of 13,386 and 13,082 shares were also acquired at the same respective weighted-average prices.
After these trades, one indirect holding reported in Table I rose to 380,152 shares of common stock and a second to 381,338 shares, with larger indirect positions of 4,678,310 and 4,691,392 shares reported for other related entities. The filing explains that Baker Brothers’ principals and advisory entities may be deemed to have indirect pecuniary interests through their limited partnership and advisory relationships, while expressly disclaiming beneficial ownership beyond their economic interests.
Entrada Therapeutics (TRDA) reported an insider share sale by a major holder. On 11/14/2025, an entity affiliated with director and 10% owner Kush M. Parmar, M.D., Ph.D., sold 200,000 shares of Entrada Therapeutics common stock in an open-market transaction at a weighted average price of $8.80 per share, with individual sale prices ranging from $8.80 to $9.023.
Following this transaction, 5AM Ventures V, L.P. is shown as beneficially owning 2,963,066 shares indirectly, and 5AM Opportunities I, L.P. is shown as beneficially owning 1,093,313 shares indirectly. Dr. Parmar may be deemed to share voting and investment power over these positions through general partner entities, but he disclaims beneficial ownership except to the extent of his pecuniary interest.
Entrada Therapeutics, Inc. (TRDA) reported an insider transaction by funds affiliated with 5AM Venture Management. On 11/14/2025, the reporting persons sold 200,000 shares of Entrada common stock at a weighted average price of $8.80 per share, with individual trades executed between $8.80 and $9.023. After this sale, one fund held 2,963,066 shares directly, and another affiliated fund held 1,093,313 shares indirectly. The filing notes that managing members of the general partners may be deemed to share voting and investment power over these holdings and that some of them disclaim beneficial ownership beyond their economic interest.
Entrada Therapeutics (TRDA) filed a Form S-3 shelf registration to offer up to $400,000,000 of securities, including common stock, preferred stock, debt securities, warrants and units, to be sold from time to time after effectiveness. The filing also includes a $150,000,000 at-the-market (ATM) program for common stock via a sales agreement prospectus, which is part of the $400,000,000 aggregate.
The company may sell securities in one or more offerings using various methods described under “Plan of Distribution,” and intends to use any net proceeds for general corporate purposes, including R&D and working capital. Shares outstanding were 38,219,232 as of September 30, 2025. As of the same date, cash, cash equivalents and marketable securities were $326.8 million, which management believes funds operations into the third quarter of 2027.
Entrada Therapeutics (TRDA) filed its Q3 2025 10‑Q, reporting a sharp year-over-year step-down in collaboration revenue and a return to losses as prior-period milestone revenue tapered. Collaboration revenue was $1.6 million for the quarter versus $19.6 million a year ago, and $24.1 million for the nine months versus $173.4 million in 2024. Research and development expenses rose to $38.4 million in Q3 (from $31.3 million), reflecting advancing DMD programs; general and administrative expenses were $10.3 million (from $10.0 million).
The company posted a net loss of $44.1 million for Q3 (vs. $14.0 million loss) and a net loss of $104.6 million year‑to‑date (vs. $64.5 million income), with Q3 EPS of $(1.06). Cash, cash equivalents and marketable securities totaled $326.8 million as of September 30, 2025, which management states is sufficient to fund operations into the third quarter of 2027. Operating cash use was $96.3 million year‑to‑date. Deferred revenue declined to $0.5 million, consistent with revenue recognition on the Vertex collaboration.
Pipeline updates include ongoing Phase 1/2 studies for ENTR‑601‑44 and ENTR‑601‑45 in DMD, UK filing for ENTR‑601‑50, and a planned ENTR‑601‑51 filing in 2026. A 20% workforce reduction in April 2025 resulted in a $1.9 million charge. Shares outstanding were 38,219,232 as of October 31, 2025.